In Brief for April 27, 2022

IASLC Releases Position Statement on Air Pollution on Earth Day

Financial Toxicity of Lung Cancer in the Netherlands

As Treatment Options in Lung Cancer Have Expanded, so Have Costs

Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis

COAST Data Support Further Research of Immunotherapy Combinations

IASLC Responds to Call for Evidence

In Brief for May 11, 2022

Alternative Dosing Strategies for Immune Checkpoint Inhibitors

US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective

Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System